Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Better Living through Proteomics

Published: Monday, September 09, 2013
Last Updated: Monday, September 09, 2013
Bookmark and Share
As a patient facing illness, knowing what’s ailing you can bring peace of mind and, more importantly, can inform treatment decisions.

For neglected infectious diseases, accurate diagnostic tools can be revolutionary, saving lives and shaping the health of entire communities.

One of these neglected diseases is human African trypanosomiasis (HAT). Also known as African sleeping sickness, HAT is a debilitating infection that affects thousands each year. Patients are often only diagnosed in the late stage of the disease by observing the parasites in cerebrospinal fluid, after the parasite has entered the central nervous system and caused grave illness. A low-cost, rapid “dipstick” test that could analyze a drop of patient’s blood and diagnose the illness early would make a huge impact.

Researchers have spent decades looking for proteins from the parasite itself in plasma, the liquid component of blood, with the goal of developing rapid diagnostic tests. While plasma represents an ideal source of biomarkers – a simple finger-prick is sufficient for testing – the fluid has a major flaw when it comes to diagnosis: it’s a murky soup of proteins, ranging from abundant ones such as albumin and globulins to scarcer ones such as proteins from infectious organisms.

Scientists in the Broad’s Proteomics Platform have recently developed and optimized analytic methods that, for the first time, can identify parasite proteins in the plasma of infected patients. The sophisticated approach overcomes what research scientist Rushdy Ahmad calls a “mismatch in dynamic range,” by effectively “zooming in” on the proteins they’re most interested in.

He explains that the dynamic range of proteins in plasma, meaning the lowest to highest abundance, is perhaps as great as 12 orders of magnitude. In other words, the most abundant proteins are 1 trillion times more numerous than the least abundant proteins. The dynamic range of a mass spectrometer – the gold standard for analyzing proteins – is much narrower, only 4 orders of magnitude. Running plasma through a mass spectrometer will only reveal the most abundant proteins, leaving the scarcer ones hidden below the threshold of detection.

In the new method, plasma is first “immunodepleted,” removing the top 50-70 most abundant human plasma proteins, including proteins such as albumin. “We want to collapse that dynamic range,” Ahmad explains. The technique is like skimming off the fat from soup to leave the nutritious broth, vegetables, and meat. The remaining sample is then “fractionated,” breaking it into 30 smaller samples, each containing proteins of a narrower range of abundance. “Those fractions are what we inject into the mass spectrometer,” he says. “The combination of abundant protein removal and subsequent fractionation enabled the mass spec to probe deeper into the proteome, beneath all the human proteins we’re not interested in.”

In collaboration with Terry Pearson and colleagues at the University of Victoria in British Columbia, Ahmad and platform director Steve Carr applied the new method to plasma samples from patients infected with African sleeping sickness. They were able to identify more than 250 proteins from the trypanosome parasites that underlie this dangerous disease, showing promise for the method to discover biomarkers of disease in plasma that could one day be incorporated into a diagnostic test.

More work remains before African sleeping sickness can be rapidly diagnosed in the field. The researchers must learn which of the 250 proteins make the best biomarkers to develop a diagnostic test against. In addition, the samples used in this study came from patients with late stage disease, and the team hopes to identify proteins present during early stages of infection, so they are working to get more samples from the field. They may also forge a partnership with a diagnostic company to actually create the assay.

Interestingly, the study detected more than 4000 low-abundance human proteins present in the plasma, the greatest depth of coverage of the human plasma proteome to date. Carr, Ahmad, and their colleagues are currently mining data on these thousands of proteins found in plasma to look for patterns of change during illness – signatures of host response – in diseases such as tuberculosis and malaria. Those signatures could then form the basis for new a diagnostic approach, which would use patterns of change in the levels of proteins as indicators of disease. The proteomic analysis of human plasma proteins also provides a window into disease biology and insights that could guide vaccine development.

The researchers also plan to investigate other illnesses that could benefit from improved diagnosis, such as another trypanosome illness, Chagas disease, or cancers with poor diagnostics, like lung cancer, in addition to other neglected diseases. “Now this opens up the door for all these other diseases that don’t get a lot of limelight because they’re out on the periphery,” he says. “For now, the science is progressing and this work shows the technological capability for discovery.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DARPA Awards $32 Million Contract to MIT, Broad Institute Foundry
A facility at the Broad Institute of MIT and Harvard and MIT that aims to achieve the full potential of engineering biology has received a five-year, $32 million contract from the Defense Advanced Research Projects Agency (DARPA).
Monday, September 28, 2015
Diagnostics Breakthrough Brings Viral Sequencing to Doctors’ Toolkit
New screening tool produces up to 10,000-fold improvement in viral matches compared with traditional high-throughput methods.
Monday, September 28, 2015
Two Studies Identify A Detectable, Pre-Cancerous State In The Blood
Findings pave way for new lines of cancer research focused on detection and prevention.
Thursday, November 27, 2014
Targeting Cancer’s “Queen Bees” with Better Tissue Modeling
In many types of cancer, standard chemotherapy cures only a fraction of patients.
Wednesday, October 30, 2013
Understanding Triglycerides’ Role in Coronary Disease
The study leverages new genetic data from a related genome-wide association study, suggests that lowering triglyceride levels through treatment may help reduce the risk of coronary heart disease.
Wednesday, October 09, 2013
Blinding a CYCLOPS
Targeted therapies are changing cancer treatment.
Monday, August 20, 2012
Target Set on Cancer Gene MCL1
Broad Institute and Dana-Farber colleagues identify several chemical compounds that tamp down the expression of the MCL1 gene.
Friday, June 15, 2012
Broad Institute, Dana-Farber and Novartis Collaborate to Develop Cancer Cell Line Encyclopedia
Scientists have written the 'Book of Cancer Knowledge' to aid future research into drug discovery and personalized medicine.
Friday, March 30, 2012
Scientific News
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Honey’s Potential to Save Lives
The healing powers of honey have been known for thousands of years.
3-D Printed Lifelike Liver Tissue for Drug Screening
A team led by engineers at the University of California, San Diego has 3D-printed a tissue that closely mimics the human liver's sophisticated structure and function. The new model could be used for patient-specific drug screening and disease modeling.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!